Rare diseases
Investigational molecules
Locations
45 Sidney Street, 02139-4133, United States
Blueprint Medicines Corp. is active in advanced systemic mastocytosis, indolent systemic mastocytosis, and related KIT-altered blood cancers, with research also extending to SM-AHN and other mast cell disorders.
Its clinical portfolio in this area includes therapies aimed at controlling mast cell disease activity and addressing symptom burden in both adult and pediatric settings.
Blueprint Medicines Corp. runs clinical trials in conditions such as Systemic mastocytosis, Indolent systemic mastocytosis, Neoplasm malignant, Urticaria chronic, among others.
Clinical trials run by this sponsor – those enrolling participants first.
Study of Avapritinib for Adults with Systemic Mastocytosis Who Previously Participated in an Avapritinib Study
BelgiumStudy of Elenestinib for Patients with Indolent Systemic Mastocytosis
AustriaStudy of BLU-451 for Patients with Advanced Cancers Having EGFR Exon20 Insertion Mutations
SpainStudy of BLU-808 tablets compared to placebo in adults with chronic inducible urticaria and chronic spontaneous urticaria
DenmarkStudy of BLU-263 and Azacitidine for Patients with Advanced Systemic Mastocytosis and Other KIT Altered Blood Cancers
BelgiumStudy of Avapritinib for Children with Solid Tumors Linked to KIT or PDGFRA Signaling
AustriaStudy on the Safety and Effectiveness of BLU-222 Alone and with Drug Combination for Patients with Advanced Solid Tumors, Including Breast and Ovarian Cancer
BelgiumStudy of Avapritinib for Patients with Indolent Systemic Mastocytosis Not Adequately Managed by Standard Therapy
BelgiumIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
